Background Varying conceptualizations of treatment‐resistant depression (TRD) have made
translating research findings or systematic reviews into clinical practice guidelines …

Depression is the third leading cause of disability in the world. Depressive symptoms may
be reduced within several weeks after the start of conventional antidepressants, but …

Background In the past two decades, subanaesthetic doses of ketamine have been
demonstrated to have rapid and sustained antidepressant effects, and accumulating …

Although deep brain stimulation (DBS) is an established treatment choice for Parkinson's
disease (PD), essential tremor and movement disorders, its effectiveness for the …

Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays
a fast antidepressant activity in treatment-resistant depression and in rodent models of …

The discovery of ketamine as a rapid-acting antidepressant led to a new era in the
development of neuropsychiatric therapeutics, one characterized by an antidepressant …

BackgroundDepression is considered to have the highest disability burden of all conditions.
Although treatment-resistant depression (TRD) is a key contributor to that burden, there is …

Introduction: Depression is one of the most disabling diseases worldwide. Approximately
one-third of depressed patients are treatment-resistant to the currently available …

This narrative review aims to provide an overview of the current literature on the
pharmacology, safety, efficacy and tolerability of intranasal esketamine, the S-enantiomer of …

Recommendations include using large prospective observational studies followed by
pragmatic trials rather than smaller, expensive controlled treatment trials for preliminary …